The original disclosure in Japanese was released on November 10, 2022 at 16:00 (GMT+9)

Consolidated Financial Statements for the Second Quarter Ended September 30, 2022 FY2023 (April 1, 2022 - March 31, 2023) [UNAUDITED]

Company name: Takara Holdings Inc.
Stock exchange listings: Tokyo Stock Exchange (PRIME section)
Code number: 2531
URL: https://www.takara.co.jp/
Company representative: Mutsumi Kimura, President
Contact: Masakazu Usami, General Manager of Financial & Investor Relations Dept.
TEL : (075)241-5124

Quarterly statement filing date(as planned): November 11, 2022

Notes:
1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the six months ended September 30, 2022 (April 1, 2022 - September 30, 2022)

(1) Consolidated operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Six months ended September 30, 2022		Six months ended September 30, 2021	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	164,279	16.3	141,213	10.5
Operating income (loss)	19,614	(9.3)	21,616	273.8
Ordinary income (loss)	19,972	(8.7)	21,884	268.4
Net income (loss) attributable to owners of the parent	10,873	8.2	10,050	263.9
Net income (loss) per share (Yen)	55.00		50.84	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income (loss)	30,213	43.5	21,056	765.4

(2) Consolidated financial position

	As of September 30, 2022	As of March 31, 2022
	(Millions of yen)	(Millions of yen)
Total assets	366,273	362,438
Net assets	244,317	224,555
Equity ratio (%)	53.3	49.8
(Reference) Equity	195,359	180,420

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2022	Year ending March 31, 2023	Year ending March 31, 2023 (Forecast)
First quarter end	-	-	-
Second quarter end	-	-	-
Third quarter end	-	-	-
Year end	37.00	-	34.00
Annual	37.00	-	34.00

Note: Correction of dividend forecast from the most recent dividend forecast: Yes

3. Forecast for the year ending March 31, 2023 (April 1, 2022 - March 31, 2023)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ending March 31, 2023	
	(Millions of yen)	(%)
Net sales	347,000	15.3
Operating income (loss)	35,400	(18.3)
Ordinary income (loss)	36,000	(16.7)
Net income (loss) attributable to owners of the parent	18,900	(9.0)
Net income per share (Yen)	95.60	

Note: Correction of financial forecast from the most recent financial forecast: Yes

4. Others

(1) Material changes in subsidiaries during this period
(Changes in specified subsidiaries that caused a change in the scope of consolidation): No

(2) Accounting procedures specific to quarterly consolidated financial statements : No

(3) Changes in accounting policies, accounting estimates and retrospective restatement

1) Changes based on revisions of accounting standard: No

2) Changes other than ones based on revisions of accounting standard: No

3) Changes in accounting estimates: No

4) Restatement: No

(4) Number of outstanding shares (common stock)

1) Number of outstanding shares at the end of each period (Treasury stocks are included):

As of September 30, 2022 : 199,699,743 shares
As of March 31, 2022 : 199,699,743 shares

2) Number of treasury stocks at the end of each period:

As of September 30, 2022 : 1,995,602 shares
As of March 31, 2022 : 1,995,577 shares

3) Average number of outstanding shares in each period

Six months ended September 30, 2022 : 197,704,145 shares
Six months ended September 30, 2021 : 197,704,258 shares

Contents of the attached document

1. Qualitative Information for the Six Months Ended September 30, 2022…… 2

(1) Consolidated Financial Results …… 2

(2) Consolidated Financial Position …… 3

(3) Qualitative Information Regarding Consolidated Forecasts…… 4

2. Consolidated Quarterly Financial Statements and Primary Notes…… 6

(1) Consolidated Balance Sheets…… 6

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income…… 8

(Consolidated Statements of Income) …… 8
(For the Six Months Ended September 30, 2022 and 2021)

(Consolidated Statements of Comprehensive Income) …… 9
(For the Six Months Ended September 30, 2022 and 2021)

(3) Consolidated Statements of Cash Flows …… 10

(4) Notes to Consolidated Financial Statements…… 11

(Notes on Premise of Going Concern) …… 11

(Notes on Material Changes in Shareholders' Equity) …… 11

(Segment Information) …… 11

(Revenue Recognition) …… 12

(Significant Subsequent Events) …… 13

○ Supplement for the Consolidated Quarterly Financial Statements

1. Qualitative Information for the Six Months Ended September 30, 2022

(1) Consolidated Financial Results

In the six months ended September 30, 2022, net sales increased 16.3% year on year to ¥164,279 million, gross profit increased 6.5% year on year to ¥57,879 million, and SG&A expenses increased 16.9% year on year to ¥38,264 million. Operating income decreased 9.3% year on year to ¥19,614 million, ordinary income decreased 8.7% year on year to ¥19,972 million, and net income attributable to owners of the parent increased 8.2% year on year to ¥10,873 million.

Results by business segment were as follows.

[Takara Shuzo]

In the six months ended September 30, 2022, although sales of sake decreased slightly, partly due to an increase in demand ahead of schedule in September prior to price revisions, sales of shochu, light-alcohol refreshers, *Hon Mirin*, and raw alcohol increased.

As a result, net sales for Takara Shuzo increased 7.3% year on year to ¥61,820 million. Cost of sales increased 10.2% year on year to ¥47,765 million, mainly due to the impact of rising resource and raw material prices, and gross profit decreased 1.7% year on year to ¥14,055 million. SG&A expenses decreased 0.2% year on year to ¥11,996 million due to a decrease in personnel expenses. Operating income was down 9.3% year on year to ¥2,059 million.

[Takara Shuzo International Group]

In the six months ended September 30, 2022, net sales of the Overseas Alcoholic Beverages Business increased year on year mainly due to continued growth in sales of whiskey in the U.K. and the U.S. as well as an increase in sales of sake. Net sales of the Japanese Food Wholesale Business in overseas markets also increased as the eating and drinking establishment market continued to perform well.

As a result, net sales for the Takara Shuzo International Group increased 36.4% year on year to ¥63,730 million. Cost of sales increased 37.8% year on year to ¥43,748 million, mainly due to the impact of continuing high sea freight costs. Consequently, gross profit increased 33.3% year on year to ¥19,981 million. SG&A expenses were up 34.1% year on year to ¥14,322 million, primarily due to an increase in personnel expenses and transportation costs, and operating income was up 31.5% year on year to ¥5,658 million.

[Takara Bio Group]

In the six months ended September 30, 2022, although sales of instruments and CDMO decreased year on year, sales of reagents and gene therapy increased. In particular, sales of reagents for general research use increased, and sales of testing-related reagents for COVID-19 grew as a result of the impact from the seventh wave of COVID-19 infections.

As a result, net sales for the Takara Bio Group increased 3.3% year on year to ¥32,587 million. Cost of sales increased 31.1% year on year to ¥10,562 million, mainly due to a change in sales mix. Consequently, gross profit decreased 6.3% year on year to ¥22,025 million. SG&A expenses were up 18.8% year on year to ¥11,154 million, primarily due to an increase in personnel expenses and R&D expenses. Operating income decreased 22.9% year on year to ¥10,870 million.

[Other]

In the six months ended September 30, 2022, net sales of the Other segment increased 6.5% year on year to ¥15,577 million due to continued strong import and sale of wine. Cost of sales increased 5.6% year on year to ¥13,392 million. Consequently, gross profit increased 12.6% year on year to ¥2,184 million. SG&A expenses rose 3.4% year on year to ¥941 million due to an increase in transportation costs, and operating income was up 20.8% year on year to ¥1,243 million.

Breakdown of sales results by product category

Segment / Product category	Equivalent Period of Previous Fiscal Year (From April 1, 2021, to September 30, 2021) Amount (Millions of yen)	Period under Review (From April 1, 2022, to September 30, 2022) Amount (Millions of yen)	YoY Comparison (%)
Takara Shuzo			
Shochu	19,315	19,998	3.5
Sake	4,718	4,697	(0.4)
Light-alcohol refreshers	18,808	20,525	9.1
Other alcoholic beverages	2,529	2,823	11.6
Hon Mirin	4,258	4,710	10.6
Other seasonings	4,079	4,321	5.9
Raw alcohol, etc.	3,922	4,743	20.9
Total	57,633	61,820	7.3
Takara Shuzo International Group			
Overseas Alcoholic Beverages Business	7,005	8,287	18.3
Japanese Food Wholesales Business in overseas markets	40,410	56,421	39.6
Other	29	2,812	—
Elimination of intra-Group transaction on consolidation	(710)	(3,791)	—
Total	46,734	63,730	36.4
Takara Bio Group			
Reagents	24,988	27,565	10.3
Instruments	712	694	(2.5)
CDMO	4,732	3,183	(32.7)
Gene therapy	1,117	1,144	2.3
Total	31,551	32,587	3.3
Reported segment total	135,919	158,138	16.3
Other	14,624	15,577	6.5
Segment total	150,544	173,715	15.4
Sales not allocated to business segments and intersegment transactions	(9,331)	(9,435)	—
Total	141,213	164,279	16.3

Notes: 1. Amounts include alcohol tax.

2. Net sales of GMP grade (for manufacturing regenerative medical products) reagents, etc., which had been included in Takara Bio Group's "Reagents" until the fiscal year ended March 31, 2022, will be included in "Gene therapy" from the first quarter. The results for the equivalent period of the previous fiscal year presented in this table have been restated to reflect this change.

(2) Consolidated Financial Position

As of September 30, 2022, current assets were ¥233,028 million, an increase of ¥705 million compared with that at the end of the previous fiscal year. This was primarily due to increases in notes and accounts receivable-trade of ¥6,127 million, merchandise and finished goods of ¥6,767 million, and other in current assets such as accounts receivable-other of ¥1,100 million offset by a decrease in cash and deposits of ¥13,370 million. Noncurrent assets were ¥133,244 million, an increase of ¥3,129 million compared with that at the end of the previous fiscal year. This was primarily due to increases in property, plant and equipment of ¥4,024 million and intangible assets of ¥1,005 million offset by a decrease in investments and other assets of ¥1,900 million.

As a result, total assets were ¥366,273 million, an increase of ¥3,835 million compared with that at the end of the previous fiscal year.

As of September 30, 2022, current liabilities were ¥62,892 million, a decrease of ¥16,258 million compared with that at the end of the previous fiscal year. This was primarily due to decreases in current portion of bonds of ¥10,000 million, income taxes payable of ¥2,121 million, and other under current liabilities of ¥3,172 million. Noncurrent liabilities were ¥59,063 million, an increase of ¥332 million compared with that at the end of the previous fiscal year.

As a result, total liabilities were ¥121,956 million, a decrease of ¥15,926 million compared with that at the end of the previous fiscal year.

As of September 30, 2022, total net assets were ¥244,317 million, an increase of ¥19,761 million compared with that at the end of the previous fiscal year. This was primarily due to increases in retained earnings of ¥3,558 million due to net income attributable to owners of the parent of ¥10,873 million and dividends from surplus of ¥7,315 million, foreign currency translation adjustment of ¥12,628 million and noncontrolling interests of ¥4,822 million, offset by a decrease in valuation difference on available-for-sale securities of ¥1,113 million.

As a result, the equity ratio totaled 53.3%, compared with 49.8% at the end of the previous fiscal year.

In the six months ended September 30, 2022, net cash provided by operating activities decreased ¥4,566 million year on year to ¥7,231 million primarily due to income before income taxes of ¥20,815 million, depreciation and amortization of ¥4,336 million, an increase in notes and accounts receivable-trade of ¥3,541 million, an increase in inventories of ¥2,429 million, a decrease in other current liabilities of ¥3,103 million, and ¥9,123 million in income taxes paid.

Net cash used in investing activities resulted in expenditure of ¥9,553 million, a decrease in expenditure of ¥2,512 million compared to the same period of the previous fiscal year primarily due to payments into time deposits of ¥6,001 million, and purchase of property, plant and equipment and intangible assets of ¥5,093 million.

Net cash used in financing activities resulted in expenditure of ¥21,625 million, an increase in expenditure of ¥16,004 million compared to the same period of the previous fiscal year primarily due to redemption of bonds of ¥10,000 million, and cash dividends paid of ¥7,300 million.

As a result, cash and cash equivalents as of September 30, 2022, including effect of exchange rate change on cash and cash equivalents, stood at ¥55,991 million, down ¥19,738 million from the previous fiscal year-end.

(3) Qualitative Information Regarding Consolidated Forecasts

The Company has revised the full-year consolidated results forecasts published on August 4, 2022 in consideration of recent performance trends.

For the fiscal year ending March 31, 2023, net sales for Takara Shuzo and the Takara Shuzo International Group are expected to be largely in line with the previous forecast (announced on August 4, 2022). In addition, net sales for the Takara Bio Group are projected to be higher than the forecast as sales of reagents, instruments, and gene therapy are expected to exceed the forecast, with sales of reagents for general research use and testing-related reagents for COVID-19 in particular exceeding the forecast, despite net sales of CDMO falling below the forecast.

In terms of profit, although operating income posted by Takara Shuzo is expected to fall below the forecast due to further cost increases, operating income posted by the Takara Shuzo International Group is expected to exceed the forecast due to an improved gross profit margin. In addition, operating income posted by the Takara Bio Group is expected to exceed the forecast as a result of higher gross profit due to the increase in net sales.

As a result, net sales, operating income, ordinary income, and net profit attributable to owners of parent are expected to exceed the previous forecast for the Takara Group as a whole.

For the revision to the consolidated business result forecast, the Company has announced the “Revision of Consolidated Business Results Forecast and Dividend Forecast (Dividend Increase) for the Fiscal Year Ending March 31, 2023,” today (November 10, 2022). Also, for the details of forecasts for each business segment, please refer to pages 10/15-13/15 in “Supplement for the Consolidated Financial Statements.”

(Full-Year Consolidated Results Forecasts for the fiscal year ending March 31, 2023)

	Net sales	Operating income	Ordinary income	Net income attributable to owners of the parent	Net income per share
Previous forecast (A) (Published August 4, 2022)	(Millions of yen) 322,000	(Millions of yen) 31,700	(Millions of yen) 32,300	(Millions of yen) 17,300	(Yen) 87.50
Revised forecast (B)	347,000	35,400	36,000	18,900	95.60
Difference (B－A)	25,000	3,700	3,700	1,600	－
Difference (%)	7.8	11.7	11.5	9.2	－
Reference: Business results for previous fiscal year (Ended March 31, 2022)	300,918	43,354	43,230	20,769	105.05

2. Consolidated Quarterly Financial Statements and Primary Notes

(1) Consolidated Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2022	As of Sept. 30, 2022
Assets		
Current assets		
Cash and deposits	80,445	67,075
Notes and accounts receivable-trade	70,260	76,388
Merchandise and finished goods	63,172	69,940
Work in process	2,012	2,334
Raw materials and supplies	7,458	7,307
Other	9,422	10,523
Allowance for doubtful accounts	(449)	(540)
Total current assets	232,323	233,028
Noncurrent assets		
Property, plant and equipment	79,747	83,771
Intangible assets		
Goodwill	10,070	11,046
Other	5,290	5,319
Total intangible assets	15,360	16,366
Investments and other assets		
Investment securities	29,228	27,460
Other	5,843	5,709
Allowance for doubtful accounts	(64)	(64)
Total investments and other assets	35,006	33,106
Total noncurrent assets	130,114	133,244
Total assets	362,438	366,273

(Millions of Yen)

	As of Mar. 31, 2022	As of Sept. 30, 2022
Liabilities		
Current liabilities		
Notes and accounts payable-trade	20,973	21,237
Short-term loans payable	5,497	4,792
Current portion of bonds	10,000	—
Accrued alcohol tax	7,172	7,058
Accrued expenses	5,579	5,317
Income taxes payable	6,602	4,480
Provision	3,516	3,370
Other	19,809	16,636
Total current liabilities	79,151	62,892
Noncurrent liabilities		
Bonds payable	20,000	20,000
Long-term loans payable	15,248	15,171
Net defined benefit liability	8,944	8,879
Other	14,537	15,012
Total noncurrent liabilities	58,730	59,063
Total liabilities	137,882	121,956
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	2,499	1,918
Retained earnings	149,933	153,492
Treasury stock	(1,682)	(1,682)
Total shareholders' equity	163,976	166,954
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	12,216	11,103
Deferred gains or losses on hedges	412	784
Foreign currency translation adjustment	4,330	16,959
Remeasurements of defined benefit plans	(515)	(441)
Total accumulated other comprehensive income	16,443	28,405
Noncontrolling interests	44,135	48,957
Total net assets	224,555	244,317
Total liabilities and net assets	362,438	366,273

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

(Consolidated Statements of Income)

(For the Six Months Ended September 30, 2022 and 2021)

(Millions of Yen)

	FY2022 (Apr. 1, 2021 – Sept. 30, 2021)	FY2023 (Apr. 1, 2022 – Sept. 30, 2022)
Net sales	141,213	164,279
Cost of sales	86,872	106,400
Gross profit	54,340	57,879
Selling, general and administrative expenses	32,724	38,264
Operating income	21,616	19,614
Nonoperating income		
Dividends income	311	445
Other	357	452
Total nonoperating income	669	898
Nonoperating expenses		
Interest expenses	160	149
Share of loss of entities accounted for using equity method	54	113
Foreign exchange losses	7	113
Other	177	163
Total nonoperating expenses	400	539
Ordinary income	21,884	19,972
Extraordinary income		
Gain on sale of noncurrent assets	80	252
Insurance claim income	100	652
National subsidies	1,188	63
Total extraordinary income	1,368	967
Extraordinary loss		
Loss on sale and retirement of noncurrent assets	97	45
Loss on tax purpose reduction entry of non-current assets	1,188	63
Loss on voluntary product recall	1,567	—
Other	—	16
Total extraordinary losses	2,853	125
Income before income taxes	20,400	20,815
Income taxes-current	6,396	5,405
Income taxes-deferred	(354)	580
Total income taxes	6,041	5,985
Net income	14,358	14,829
Net income attributable to the noncontrolling interest	4,308	3,956
Net income attributable to owners of the parent	10,050	10,873

(Consolidated Statements of Comprehensive Income)

(For the Six Months Ended September 30, 2022 and 2021)

(Millions of Yen)

	FY2022 (Apr. 1, 2021 – Sept. 30, 2021)	FY2023 (Apr. 1, 2022 – Sept. 30, 2022)
Net income	14,358	14,829
Other comprehensive income		
Valuation difference on available-for-sale securities	355	(1,113)
Deferred gains or losses on hedges	10	372
Foreign currency translation adjustment	6,249	16,041
Remeasurements of defined benefit plans	81	82
Total other comprehensive income	6,697	15,383
Comprehensive income	21,056	30,213
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	15,464	22,835
Comprehensive income attributable to noncontrolling interest	5,591	7,377

(3) Consolidated Statements of Cash Flows

(Millions of Yen)

	FY2022 (Apr. 1, 2021 – Sept. 30, 2021)	FY2023 (Apr. 1, 2022 – Sept. 30, 2022)
Net cash provided by (used in) operating activities		
Income before income taxes	20,400	20,815
Depreciation and amortization	4,061	4,336
Amortization of goodwill	432	472
Increase (decrease) in provision	(1,169)	(297)
Interest and dividends income	(381)	(531)
Interest expenses	160	149
Loss (gain) on sales and retirement of non-current assets	17	(206)
Insurance claim income	(100)	(652)
Decrease (increase) in notes and accounts receivable-trade	(2,850)	(3,541)
Decrease (increase) in inventories	(2,472)	(2,429)
Increase (decrease) in notes and accounts payable-trade	1,008	(1,131)
Increase (decrease) in accrued consumption taxes	(1,316)	1,371
Increase (decrease) in other current liabilities	343	(3,103)
Other, net	(988)	87
Subtotal	17,144	15,338
Interest and dividends income received	411	541
Interest expenses paid	(162)	(177)
Income taxes paid	(6,365)	(9,123)
Proceeds from insurance income	100	652
Subsidies received	671	—
Net cash provided by (used in) operating activities	11,798	7,231
Net cash provided by (used in) investing activities		
Payments into time deposits	(10,757)	(6,001)
Proceeds from withdrawal of time deposits	2,119	1,270
Purchase of property, plant and equipment and intangible assets	(6,827)	(5,093)
Proceeds from sale of property, plant and equipment and intangible assets	107	409
Subsidies received	3,349	32
Other, net	(57)	(171)
Net cash provided by (used in) investing activities	(12,066)	(9,553)
Net cash provided by (used in) financing activities		
Net increase (decrease) in short-term borrowings	(330)	(526)
Repayments of long-term borrowings	(31)	(311)
Redemption of bonds	—	(10,000)
Cash dividends paid	(4,144)	(7,300)
Dividends paid to noncontrolling interests	(753)	(1,563)
Repayments of lease obligations	(348)	(369)
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation	—	(1,551)
Other, net	(12)	(2)
Net cash provided by (used in) financing activities	(5,620)	(21,625)
Effect of exchange rate change on cash and cash equivalents	1,802	4,208
Net increase (decrease) in cash and cash equivalents	(4,085)	(19,738)
Cash and cash equivalents at beginning of period	62,860	75,729
Cash and cash equivalents at end of period	58,775	55,991

(4) Notes to Consolidated Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2021 to September 30, 2021)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	57,202	46,564	31,551	135,318	5,895	141,213	-	141,213
Intersegment	431	170	0	601	8,729	9,331	(9,331)	-
Total	57,633	46,734	31,551	135,919	14,624	150,544	(9,331)	141,213
Segment income (loss)	2,270	4,304	14,105	20,680	1,029	21,709	(93)	21,616

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business, the transportation business, and the wine import and sale business.

2. The adjustment to segment income (loss) of ¥(93) million comprises intersegment eliminations of ¥2 million and loss of the Company not allocated to business segments of ¥(96) million.

3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No items to report.

II. Period under Review (From April 1, 2022, to September 30, 2022)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	61,337	63,608	32,584	157,530	6,749	164,279	-	164,279
Intersegment	483	121	2	608	8,827	9,435	(9,435)	-
Total	61,820	63,730	32,587	158,138	15,577	173,715	(9,435)	164,279
Segment income (loss)	2,059	5,658	10,870	18,588	1,243	19,831	(216)	19,614

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business, the transportation business, and the wine import and sale business.

2. The adjustment to segment income (loss) of ¥(216) million comprises intersegment eliminations of ¥14 million and loss of the Company not allocated to business segments of ¥(231) million.

3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No items to report.

(Revenue Recognition)

Information on breakdown of revenue from contracts with customers

Equivalent Period of Previous Fiscal Year (From April 1, 2021 to September 30, 2021)

(Millions of yen)

	Reported Segment				Other (Note)	Total
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal		
Alcoholic Beverages Business	57,202	6,155	-	63,358	2,029	65,387
Japanese Food Wholesales Business in overseas markets	-	40,408	-	40,408	-	40,408
Bio	-	-	31,551	31,551	-	31,551
Other	-	-	-	-	3,562	3,562
Revenue earned from contracts with customers	57,202	46,564	31,551	135,318	5,592	140,910
Other revenue	-	-	-	-	302	302
Net sales to external customers	57,202	46,564	31,551	135,318	5,895	141,213

Note: Other includes business segments that are not part of reported segments, under which revenue from the import and sale of wine and from freight delivery services is included in “Revenue earned from contracts with customers,” and revenue from real estate rental is included in “Other revenue” based on ASBJ Statement No. 13 “Accounting Standard for Lease Transactions.”

Period under Review (From April 1, 2022, to September 30, 2022)

(Millions of yen)

	Reported Segment				Other (Note)	Total
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal		
Alcoholic Beverages Business	61,337	7,188	-	68,525	2,800	71,325
Japanese Food Wholesales Business in overseas markets	-	56,420	-	56,420	-	56,420
Bio	-	-	32,584	32,584	-	32,584
Other	-	-	-	-	3,646	3,646
Revenue earned from contracts with customers	61,337	63,608	32,584	157,530	6,446	163,977
Other revenue	-	-	-	-	302	302
Net sales to external customers	61,337	63,608	32,584	157,530	6,749	164,279

Note: Other includes business segments that are not part of reported segments, under which revenue from the import and sale of wine and from freight delivery services is included in “Revenue earned from contracts with customers,” and revenue from real estate rental is included in “Other revenue” based on ASBJ Statement No. 13 “Accounting Standard for Lease Transactions.”

(Significant Subsequent Events)

(Termination of a significant contract)

At a meeting of the Board of Directors held on November 10, 2022, Takara Bio Inc. ("Takara Bio"), a consolidated subsidiary of the Company, resolved to terminate its agreement on co-development and exclusive marketing of NY-ESO-1 siTCR (the "Agreement") with Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), and, with the consent of both companies, terminated the Agreement as of November 10, 2022.

(1) Reasons for the termination

Takara Bio and Otsuka have been jointly developing NY-ESO-1・siTCR® gene therapy (hereinafter, the "product") for synovial sarcoma in Japan and preparing for the submission for manufacturing and marketing approval. However after comprehensive discussions between the two companies on policies and strategies related to this product, Takara Bio and Otsuka have agreed to terminate this agreement. This decision is not due to any efficacy or safety issues of the product.

(2) Name of the other party in the Agreement

Otsuka Pharmaceutical Co., Ltd.

(3) Date of termination of the Agreement

November 10, 2022

(4) Details of the Agreement

Takara Bio and Otsuka co-develop the product in Japan. Takara Bio grants Otsuka exclusive rights to market the product for all indications in Japan and the first refusal right for nine Asian countries outside Japan. Takara Bio receives an upfront payment, milestone payments based on the progress of development and, following the launch of the product, a certain running royalty linked to net sales and a lump-sum payment based on the achievement of net sales targets. In addition, Takara Bio retains the rights to manufacture the product for clinical trials and the further commercialization and supply Otsuka on a chargeable basis.

(5) Significant impact of the termination of the Agreement on operating activities, etc.

The technical, intellectual property and other rights of the product licensed to Otsuka under the agreement are returned to Takara Bio with the termination. The milestone payments, lump-sum payments and the sales revenue on trial products will not occur.

2023年3月期
第2四半期決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Second Quarter Ended September 30, 2022

1. 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-
① グループ別要約損益計算書
Consolidated Statements of Income by Business Group (Summary)
② 要約貸借対照表
Consolidated Balance Sheets (Summary)

2. 宝酒造
Takara Shuzo
要約損益計算書
Statements of Income (Summary)

3. 宝酒造インターナショナルグループ
Takara Shuzo International Group
要約損益計算書
Statements of Income (Summary)

4. タカラバイオグループ
Takara Bio Group
要約損益計算書
Statements of Income (Summary)

5. 6年間の財務サマリー(グループ別)
Six-Year Financial Summary by Business Group

6. 2023年3月期第2四半期　参考資料
Reference Data for the Second Quarter Ended September 30, 2022

7. 2023年3月期 業績予想
Financial forecast for the year ending March 31, 2023
① 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-
② 宝酒造
Takara Shuzo
③ 宝酒造インターナショナルグループ
Takara Shuzo International Group
④ タカラバイオグループ
Takara Bio Group

8. 2023年3月期　参考資料
Reference Data for the year ending March 31, 2023

宝ホールディングス株式会社
TAKARA HOLDINGS INC.
財務・IR部　Financial & Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5127
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　財務・IR部
Takara Holdings Inc. Financial & Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5127
E-Mail ir@takara.co.jp

1. 宝ホールディングス（連結） :Takara Holdings Inc. -Consolidated-

① グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

（百万円 :Millions of Yen）

	2022年3月期 第2四半期累計	2023年3月期 第2四半期累計 Apr. 1, 2022 - Sep. 30, 2022		対前期 Change from FY2022(1Q-2Q)		対8/4予想 Change from forecast announced Aug. 2022	
	実績(a) FY2022(1Q-2Q) Actual (a)	8/4予想(b) FY2023(1Q-2Q) Forecast announced Aug. 2022 (b)	実績(c) FY2023(1Q-2Q) Actual (c)	増減(c−a) Change (c-a)	率(c/a−1) YOY% (c/a-1)	増減(c−b) Change (c-b)	率(c/b−1) YOY% (c/b-1)
宝酒造 Takara Shuzo	57,633	61,932	61,820	4,187	7.3%	△ 111	△0.2%
宝酒造インターナショナルグループ Takara Shuzo International Group	46,734	63,595	63,730	16,995	36.4%	135	0.2%
タカラバイオ グループ Takara Bio Group	31,551	27,744	32,587	1,035	3.3%	4,843	17.5%
その他 Other	14,624	15,401	15,577	952	6.5%	176	1.1%
調整額 Adjustment	△ 9,331	△ 9,672	△ 9,435	△ 104	−	236	−
売上高 Net sales	141,213	159,000	164,279	23,066	16.3%	5,279	3.3%
売上原価 Cost of sales	86,872	103,700	106,400	19,527	22.5%	2,700	2.6%
売上総利益 Gross profit	54,340	55,300	57,879	3,538	6.5%	2,579	4.7%
運送費、保管料 Transportation and storage	5,752	6,700	6,468	716	12.5%	△ 231	△3.5%
広告宣伝費 Advertising	1,122	1,200	1,176	53	4.8%	△ 23	△2.0%
販売促進費 Sales promotion	1,697	1,900	1,850	153	9.0%	△ 49	△2.6%
研究開発費 Research and development	2,847	3,900	4,034	1,187	41.7%	134	3.5%
管理費、その他 Other, net	21,305	24,900	24,734	3,429	16.1%	△ 165	△0.7%
販売費及び一般管理費 SG&A expenses	32,724	38,600	38,264	5,540	16.9%	△ 335	△0.9%
宝酒造 Takara Shuzo	2,270	1,557	2,059	△ 211	△9.3%	502	32.3%
宝酒造インターナショナルグループ Takara Shuzo International Group	4,304	5,570	5,658	1,354	31.5%	88	1.6%
タカラバイオ グループ Takara Bio Group	14,105	8,641	10,870	△ 3,234	△22.9%	2,229	25.8%
その他 Other	1,029	1,207	1,243	213	20.8%	36	3.0%
調整額 Adjustment	△ 93	△ 275	△ 216	△ 123	−	58	−
営業利益（△：損失） Operating income(Δ:loss)	21,616	16,700	19,614	△ 2,001	△9.3%	2,914	17.5%
受取利息・配当金 Interest and Dividends income	381	550	531	150	39.4%	△ 18	△3.4%
その他営業外収益 Other, net	287	250	366	78	27.4%	116	46.6%
営業外収益 Non-operating income	669	800	898	229	34.2%	98	12.3%
支払利息 Interest and discounts expenses	160	150	149	△ 11	△6.9%	△ 0	△0.3%
その他営業外費用 Other, net	239	150	390	150	62.7%	240	160.2%
営業外費用 Non-operating expenses	400	300	539	139	34.8%	239	79.9%
経常利益（△：損失） Ordinary income(Δ:loss)	21,884	17,200	19,972	△ 1,911	△8.7%	2,772	16.1%
特別利益 Extraordinary income	1,368	250	967	△ 401	△29.3%	717	287.1%
特別損失 Extraordinary loss	2,853	50	125	△ 2,728	△95.6%	75	150.5%
税金等調整前四半期純利益（△：損失） Income before income taxes(Δ:loss)	20,400	17,400	20,815	415	2.0%	3,415	19.6%
法人税、住民税及び事業税 Current income taxes	6,396	5,200	5,405	△ 991	△15.5%	785	15.1%
法人税等調整額 Deferred income taxes	△ 354		580	935	−		
四半期純利益（△：損失） Net income(Δ:loss)	14,358	12,200	14,829	471	3.3%	2,629	21.6%
非支配株主に帰属する四半期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	4,308	3,100	3,956	△ 351	△8.2%	856	27.6%
親会社株主に帰属する四半期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	10,050	9,100	10,873	823	8.2%	1,773	19.5%
設備投資額（有形・無形） Capital expenditures	8,811		3,513	△ 5,298	△60.1%	△ 415	△10.6%
減価償却費（有形・無形） Depreciation and Amortization	4,061	4,500	4,336	275	6.8%	△ 163	△3.6%
のれん償却額 Amortization of goodwill	432	500	472	40	9.3%	△ 27	△5.5%

営業外収益 Non-operating income	受取利息 85、受取配当金 445 など Interest income 85, Dividends income 445 etc.
営業外費用 Non-operating expenses	支払利息 122、持分法による投資損失 113、為替差損 113 など Interest expense 122, Equity losses of affiliated companies 113, Foreign exchange losses 113 etc.
特別利益 Extraordinary income	受取保険金 652、国庫補助金 63 など（前期:国庫補助金 1,188 など） Insurance claim income 652, National subsidies 63 etc. (FY2022:National subsidies 1,188)
特別損失 Extraordinary loss	固定資産圧縮損 63 など（前期: 固定資産圧縮損 1,188、製品自主回収関連 1,567 など） Loss on tax purpose reduction entry of non-current assets 63 etc. (FY2022: Loss on tax purpose reduction entry of non-current assets 1,188, Loss on product recall 1,567)

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

資産の部 :Assets

（百万円 :Millions of Yen）

	2022年3月期末 As of Mar. 31, 2022	2023年3月期第2四半期末 As of Sep. 30, 2022	増減 Change	主な増減理由 Reference
（流動資産） (Total current assets)	232,323	233,028	705	（億円 :One hundred millions of Yen）
現金及び預金 Cash and deposits	80,445	67,075	△ 13,370	うち 社債償還 △100.0 Redemption of Bonds
受取手形及び売掛金 Notes and accounts receivable-trade	70,260	76,388	6,127	
有価証券 Marketable securities	1,179	396	△ 782	
棚卸資産 Inventories	72,643	79,582	6,939	
その他 Other current assets	8,243	10,126	1,882	
貸倒引当金 Allowance for doubtful accounts	△ 449	△ 540	△ 91	
（固定資産） (Total fixed assets)	130,114	133,244	3,129	
〔有形固定資産〕 [Property, plant and equipment]	79,747	83,771	4,024	
建物及び構築物 Buildings and structures	32,682	34,658	1,975	（当期の有形・無形固定資産の主な増減内訳） Reference of Property, plant and equipment and Intangible assets
機械装置及び運搬具 Machinery, equipment and vehicles	15,006	14,705	△ 300	新規取得 TS＋6.3、TSI＋7.5、TB＋20.5 Newly purchases
土地 Land	20,170	20,739	568	減価償却 TS△11.9、TSI△9.0、TB△19.6 Depreciation
その他 Other property, plant and equipment	11,888	13,669	1,780	圧縮損 TS△0.6 compression loss
〔無形固定資産〕 [Intangible fixed assets]	15,360	16,366	1,005	
のれん Goodwill	10,070	11,046	976	
その他 Other intangible fixed assets	5,290	5,319	29	
〔投資その他の資産〕 [Investments and other assets]	35,006	33,106	△ 1,900	
投資有価証券 Investment securities	29,228	27,460	△ 1,767	うち 時価評価 TH △17.5 TS +1.1 Market valuation
その他 Other assets	5,843	5,709	△ 133	
貸倒引当金 Allowance for doubtful accounts	△ 64	△ 64	―	
資産合計 Total assets	362,438	366,273	3,835	

(TH=Takara Holdings Inc., TS=Takara Shuzo, TSI=Takara Shuzo International Group, TB=Takara Bio Group)

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

負債及び純資産 の部 :Liabilities and net assets

（百万円 :Millions of Yen）

	2022年3月期末 As of Mar. 31, 2022	2023年3月期第2四半期末 As of Sep. 30, 2022	増減 Change	主な増減理由 Reference
（流動負債） (Total current liabilities)	79,151	62,892	△ 16,258	（億円 :One hundred millions of Yen）
支払手形及び買掛金 Notes and accounts payable-trade	20,973	21,237	264	
短期借入金 Short-term loans payable	5,497	4,792	△ 704	
1年内償還予定の社債 Current portion of bonds	10,000	―	△ 10,000	TH △100.0（第13,14回普通社債 2022年4月償還） (#13,14SB Redemption Apr.2022)
未払酒税 Accrued alcohol tax	7,172	7,058	△ 114	
未払費用 Accrued expenses	5,579	5,317	△ 262	
その他 Other current liabilities	29,928	24,487	△ 5,441	
（固定負債） (Total non-current liabilities)	58,730	59,063	332	
社債 Bonds payable	20,000	20,000	―	
長期借入金 Long-term loans payable	15,248	15,171	△ 76	
退職給付に係る負債 Net defined benefit liability	8,944	8,879	△ 65	
預り金 Deposits from customers	5,089	5,083	△ 5	
その他 Other non-current liabilities	9,447	9,928	480	
負債合計 Total liabilities	137,882	121,956	△ 15,926	
資本金 Capital stock	13,226	13,226	―	
資本剰余金 Capital surplus	2,499	1,918	△ 580	
利益剰余金 Retained earnings	149,933	153,492	3,558	親会社株主に帰属する四半期純利益108、配当△73 Net income attributable to owners of the parent +108, Interest △73, etc
自己株式 Treasury stock	△ 1,682	△ 1,682	△ 0	
（株主資本） (Total owner's equity)	163,976	166,954	2,977	
その他有価証券評価差額金 Valuation difference on available-for-sale securities	12,216	11,103	△ 1,113	
繰延ヘッジ損益 Deffered gains or losses on hedges	412	784	372	
為替換算調整勘定 Translation adjustments	4,330	16,959	12,628	TSI +88, TB +37
退職給付に係る調整累計額 Remeasurements of defined benefit plans	△ 515	△ 441	73	
（その他の包括利益累計額） (Total valuation and translation adjustments)	16,443	28,405	11,961	
（非支配株主持分） (Noncontrolling interests)	44,135	48,957	4,822	
純資産合計 Total net assets	224,555	244,317	19,761	
負債純資産合計 Total liabilities and net assets	362,438	366,273	3,835	

(TH=Takara Holdings Inc., TS=Takara Shuzo, TSI=Takara Shuzo International Group, TB=Takara Bio Group)

2. 宝酒造 :Takara Shuzo

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	2022年3月期 第2四半期累計	2023年3月期 第2四半期累計 Apr. 1, 2022 - Sep. 30, 2022		対前期 Change from FY2022(1Q-2Q)		対8/4予想 Change from forecast announced Aug. 2022	
	実績(a) FY2022(1Q-2Q) Actual (a)	8/4予想(b) FY2023(1Q-2Q) Forecast announced August 2022 (b)	実績(c) FY2023(1Q-2Q) Actual (c)	増減(c-a) Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減(c-b) Change (c-b)	率(c/b-1) YOY% (c/b-1)
焼酎 Shochu	19,315	20,009	19,998	682	3.5%	△ 10	△ 0.1%
清酒 Sake	4,718	4,803	4,697	△ 21	△ 0.4%	△ 105	△ 2.2%
ソフトアルコール飲料 Light-alcohol refreshers	18,808	20,822	20,525	1,716	9.1%	△ 296	△ 1.4%
その他酒類 Other liquors	2,529	2,839	2,823	293	11.6%	△ 15	△ 0.5%
本みりん Hon Mirin	4,258	4,591	4,710	452	10.6%	119	2.6%
その他調味料 Other seasonings	4,079	4,349	4,321	242	5.9%	△ 27	△ 0.6%
原料用アルコール等 Raw alcohol	3,922	4,519	4,743	821	20.9%	224	5.0%
売上高 Net sales	57,633	61,932	61,820	4,187	7.3%	△ 111	△ 0.2%
売上原価 Cost of sales	43,341	48,073	47,765	4,423	10.2%	△ 307	△ 0.6%
売上総利益 Gross profit	14,291	13,859	14,055	△ 235	△ 1.7%	196	1.4%
運送費、保管料 Transportation and storage	3,977	4,176	4,029	52	1.3%	△ 146	△ 3.5%
広告宣伝費 Advertising	1,052	1,212	1,099	47	4.5%	△ 112	△ 9.3%
販売促進費 Sales promotion	1,059	1,091	1,072	12	1.2%	△ 18	△ 1.7%
研究開発費 Research and development	183	176	177	△ 6	△ 3.4%	1	0.7%
管理費、その他 Other, net	5,748	5,647	5,617	△ 130	△ 2.3%	△ 29	△ 0.5%
販売費及び一般管理費 SG&A expenses	12,020	12,302	11,996	△ 24	△ 0.2%	△ 305	△ 2.5%
営業利益(△:損失) Operating income(Δ:loss)	2,270	1,557	2,059	△ 211	△ 9.3%	502	32.3%
営業外収益 Non-operating income	178	325	397	219	123.1%	72	22.3%
営業外費用 Non-operating expenses	127	182	362	235	184.0%	180	99.3%
経常利益(△:損失) Ordinary income(Δ:loss)	2,321	1,700	2,094	△ 226	△ 9.8%	394	23.2%
特別利益 Extraordinary gain	110	—	63	△ 47	△ 42.9%	63	—
特別損失 Extraordinary loss	1,622	30	94	△ 1,528	△ 94.2%	64	213.6%
税金等調整前四半期純利益(△:損失) Income before income taxes(Δ:loss)	809	1,670	2,063	1,253	154.9%	393	23.5%
法人税、住民税及び事業税 Current income taxes	459	535	761	302	65.8%	154	33.7%
法人税等調整額 Deferred income taxes	△ 202		△ 147	54	—		
四半期純利益(△:損失) Net income(Δ:loss)	552	1,135	1,449	896	162.2%	314	27.7%
設備投資額(有形・無形) Capital expenditures	500		638	138	27.7%	638	—
減価償却費(有形・無形) Depreciation and Amortization	1,257	1,202	1,190	△ 66	△ 5.3%	△ 11	△ 0.9%

3. 宝酒造インターナショナルグループ :Takara Shuzo International Group

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	2022年3月期 第2四半期累計	2023年3月期 第2四半期累計 Apr. 1, 2022 - Sep. 30, 2022		対前期 Change from FY2022(1Q-2Q)		対8/4予想 Change from forecast announced Aug. 2022	
	実績(a) FY2022(1Q-2Q) Actual (a)	8/4予想(b) FY2023(1Q-2Q) Forecast announced August 2022 (b)	実績(c) FY2023(1Q-2Q) Actual (c)	増減(c−a) Change (c-a)	率(c/a−1) YOY% (c/a-1)	増減(c−b) Change (c-b)	率(c/b−1) YOY% (c/b-1)
海外酒類事業 Overseas Alcoholic beverages business	7,005	8,188	8,287	1,282	18.3%	99	1.2%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	40,410	56,458	56,421	16,010	39.6%	△ 36	△ 0.1%
その他 Other	29	2,810	2,812	2,782	−	2	0.1%
連結消去 Elimination	△ 710	△ 3,861	△ 3,791	△ 3,080	−	69	−
売上高 Net sales	46,734	63,595	63,730	16,995	36.4%	135	0.2%
売上原価 Cost of sales	31,747	43,762	43,748	12,000	37.8%	△ 13	△ 0.0%
売上総利益 Gross profit	14,987	19,833	19,981	4,994	33.3%	148	0.7%
運送費、保管料 Transportation and storage	1,517	2,278	2,253	735	48.5%	△ 24	△ 1.1%
広告宣伝費 Advertising	39	51	50	11	28.3%	△ 0	△ 0.1%
販売促進費 Sales promotion	355	496	486	130	36.6%	△ 9	△ 2.0%
管理費、その他 Other, net	8,769	11,438	11,532	2,762	31.5%	94	0.8%
販売費及び一般管理費 SG&A expenses	10,682	14,263	14,322	3,640	34.1%	59	0.4%
海外酒類事業 Overseas Alcoholic beverages business	2,145	2,332	2,466	320	14.9%	134	5.8%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	2,904	4,039	4,002	1,097	37.8%	△ 36	△ 0.9%
その他 Other	△ 491	2,229	2,232	2,724	−	3	0.2%
連結消去 Elimination	△ 254	△ 3,031	△ 3,042	△ 2,788	−	△ 11	−
営業利益(△:損失) Operating income(Δ:loss)	4,304	5,570	5,658	1,354	31.5%	88	1.6%
営業外収益 Non-operating income	81	142	187	105	129.6%	45	32.2%
営業外費用 Non-operating expenses	159	68	76	△ 83	△ 52.1%	8	12.3%
経常利益(△:損失) Ordinary income(Δ:loss)	4,226	5,644	5,769	1,543	36.5%	125	2.2%
特別利益 Extraordinary gain	2	5	0	△ 1	△ 64.2%	△ 4	△ 81.4%
特別損失 Extraordinary loss	6	2	1	△ 4	△ 78.5%	△ 0	△ 32.2%
税金等調整前四半期純利益(△:損失) Income before income taxes(Δ:loss)	4,222	5,647	5,769	1,546	36.6%	122	2.2%
法人税、住民税及び事業税 Current income taxes	1,108	1,602	1,709	601	54.2%	26	1.6%
法人税等調整額 Deferred income taxes	55		△ 81	△ 136	−		
四半期純利益(△:損失) Net income(Δ:loss)	3,059	4,045	4,141	1,081	35.3%	96	2.4%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	349	587	585	235	67.4%	△ 1	△ 0.3%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	2,709	3,458	3,555	845	31.2%	97	2.8%
設備投資額(有形・無形) Capital expenditures	462		750	288	62.6%	750	−
減価償却費(有形・無形) Depreciation and Amortization	837	1,202	904	67	8.0%	△ 298	△ 24.8%
のれん償却額 Amortization of goodwill	187	243	192	5	2.8%	△ 51	△ 21.1%

4. タカラバイオグループ :Takara Bio Group

（注）2022年8月4日時点で公表した第2四半期累計期間の業績予想において、
タカラバイオグループは2022年5月12日公表の予想を据え置いております。

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	2022年3月期 第2四半期累計	2023年3月期 Apr. 1, 2022 - Sep. 30, 2022		対前期 Change from FY2022(1Q-2Q)		対5/12予想 Change from forecast announced May. 2022	
	実績(a) FY2022(1Q-2Q) Actual (a)	5/12予想(b) FY2023(1Q-2Q) Forecast announced May. 2022 (b)	実績(c) FY2023(1Q-2Q) Actual (c)	増減(c−a) Change (c-a)	率(c/a−1) YOY% (c/a-1)	増減(c−b) Change (c-b)	率(c/b−1) YOY% (c/b-1)
試薬 Reagents	24,988	22,576	27,565	2,576	10.3%	4,989	22.1%
機器 Instruments	712	669	694	△ 17	△ 2.5%	25	3.8%
受託 CDMO	4,732	3,304	3,183	△ 1,548	△ 32.7%	△ 121	△ 3.7%
遺伝子医療 Gene Therapy	1,117	1,194	1,144	26	2.3%	△ 50	△ 4.2%
売上高 Net sales	31,551	27,744	32,587	1,035	3.3%	4,842	17.5%
売上原価 Cost of sales	8,056	8,057	10,562	2,505	31.1%	2,504	31.1%
売上総利益 Gross profit	23,495	19,686	22,025	△ 1,470	△ 6.3%	2,338	11.9%
運送費、保管料 Transportation and storage	406	367	330	△ 75	△ 18.6%	△ 36	△ 10.0%
広告宣伝費 Advertising	28	40	21	△ 6	△ 23.0%	△ 18	△ 45.7%
販売促進費 Sales promotion	305	457	306	1	0.3%	△ 150	△ 32.9%
研究開発費 Research and development	2,659	3,730	3,853	1,193	44.9%	122	3.3%
管理費、その他 Other, net	5,989	6,448	6,641	652	10.9%	193	3.0%
販売費及び一般管理費 SG&A expenses	9,389	11,044	11,154	1,764	18.8%	109	1.0%
営業利益（△：損失） Operating income(Δ:loss)	14,105	8,641	10,870	△ 3,234	△ 22.9%	2,228	25.8%
営業外収益 Non-operating income	179	139	170	△ 8	△ 4.8%	31	22.5%
営業外費用 Non-operating expenses	43	55	85	42	97.4%	29	54.2%
経常利益（△：損失） Ordinary income(Δ:loss)	14,241	8,726	10,955	△ 3,285	△ 23.1%	2,229	25.6%
特別利益 Extraordinary income	1,188	250	902	△ 286	△ 24.1%	652	261.1%
特別損失 Extraordinary loss	1,227	4	27	△ 1,200	△ 97.8%	22	497.5%
税金等調整前四半期純利益（△：損失） Income before income taxes(Δ:loss)	14,203	8,971	11,831	△ 2,371	△ 16.7%	2,860	31.9%
法人税、住民税及び事業税 Current income taxes	4,401	2,588	2,538	△ 1,862	△ 42.3%	671	25.9%
法人税等調整額 Deferred income taxes	△ 253		721	974	−		
四半期純利益（△：損失） Net income(Δ:loss)	10,054	6,383	8,572	△ 1,482	△ 14.7%	2,188	34.3%
非支配株主に帰属する四半期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	45	29	33	△ 12	△ 26.5%	4	16.1%
親会社株主に帰属する四半期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	10,009	6,354	8,538	△ 1,470	△ 14.7%	2,184	34.4%
設備投資額（有形・無形） Capital expenditures	7,676		2,056	△ 5,619	△ 73.2%	2,056	−
減価償却費（有形・無形） Depreciation and Amortization	1,670	2,043	1,962	291	17.4%	△ 80	△ 4.0%
のれん償却額 Amortization of goodwill	245	257	280	34	14.2%	23	9.0%

5. 6年間の財務サマリー（グループ別） :Six-Year Financial Summary by Business Group

宝ホールディングス（連結） :Takara Holdings Inc. -Consolidated-

（百万円 :Millions of Yen）

		2018年3月期 第2四半期 FY2018 (1Q-2Q)	2019年3月期 第2四半期 FY2019 (1Q-2Q)	2020年3月期 第2四半期 FY2020 (1Q-2Q)	2021年3月期 第2四半期 FY2021 (1Q-2Q)	2022年3月期 第2四半期 FY2022 (1Q-2Q)	2023年3月期 第2四半期 FY2023 (1Q-2Q)	前期対比 Change from FY2022(1Q-2Q) 増減 Change	前期対比 Change from FY2022(1Q-2Q) 率 YOY%
売上高	Net sales	128,855	133,987	137,502	127,784	141,213	164,279	23,066	16.3%
売上原価	Cost of sales	79,401	81,332	84,468	76,361	86,872	106,400	19,527	22.5%
（売上高原価率）	(Ratio to Net sales)	61.6%	60.7%	61.4%	59.8%	61.5%	64.8%	+3.2pt	5.3%
売上総利益	Gross profit	49,454	52,655	53,033	51,422	54,340	57,879	3,538	6.5%
販売費及び一般管理費	SG&A expenses	43,326	44,495	45,410	45,639	32,724	38,264	5,540	16.9%
（売上高販管費率）	(Ratio to Net sales)	33.6%	33.2%	33.0%	35.7%	23.2%	23.3%	+0.1pt	0.5%
営業利益（△：損失）	Operating income(Δ:loss)	6,128	8,159	7,623	5,782	21,616	19,614	△ 2,001	△ 9.3%
（売上高営業利益率）	(Ratio to Net Sales)	4.8%	6.1%	5.5%	4.5%	15.3%	11.9%	-3.4pt	△ 22.0%
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	16,328	16,459	17,011	16,885	1,697	1,850	153	9.0%
（売上高販促費率）	(Ratio to Net sales)	12.7%	12.3%	12.4%	13.2%	1.2%	1.1%	-0.1pt	△ 6.3%
研究開発費	R&D expenses	2,505	2,286	2,057	2,579	2,847	4,034	1,187	41.7%
（売上高研究開発費率）	(Ratio to Net sales)	1.9%	1.7%	1.5%	2.0%	2.0%	2.5%	+0.4pt	21.8%
設備投資額（有形・無形）	Capital expenditures	2,451	2,603	8,421	8,448	8,811	3,513	△ 5,298	△ 60.1%
減価償却費（有形・無形）	Depreciation and Amortization	3,157	3,183	3,364	3,997	4,061	4,336	275	6.8%
のれん償却額	Amortization of goodwill	407	429	424	432	432	472	40	9.3%

宝酒造 :Takara Shuzo

（百万円 :Millions of Yen）

		2018年3月期 第2四半期 FY2018 (1Q-2Q)	2019年3月期 第2四半期 FY2019 (1Q-2Q)	2020年3月期 第2四半期 FY2020 (1Q-2Q)	2021年3月期 第2四半期 FY2021 (1Q-2Q)	2022年3月期 第2四半期 FY2022 (1Q-2Q)	2023年3月期 第2四半期 FY2023 (1Q-2Q)	前期対比 Change from FY2022(1Q-2Q) 増減 Change	前期対比 Change from FY2022(1Q-2Q) 率 YOY%
売上高	Net sales	71,973	73,259	75,135	74,164	57,633	61,820	4,187	7.3%
売上原価	Cost of sales	43,360	44,144	45,586	45,183	43,341	47,765	4,423	10.2%
（売上高原価率）	(Ratio to Net sales)	60.2%	60.3%	60.7%	60.9%	75.2%	77.3%	+2.1pt	2.7%
売上総利益	Gross profit	28,613	29,115	29,549	28,981	14,291	14,055	△ 235	△ 1.7%
販売費及び一般管理費	SG&A expenses	26,621	26,839	27,467	27,355	12,020	11,996	△ 24	△ 0.2%
（売上高販管費率）	(Ratio to Net sales)	37.0%	36.6%	36.6%	36.9%	20.9%	19.4%	-1.5pt	△ 7.0%
営業利益（△：損失）	Operating income(Δ:loss)	1,991	2,275	2,082	1,626	2,270	2,059	△ 211	△ 9.3%
（売上高営業利益率）	(Ratio to Net sales)	2.8%	3.1%	2.8%	2.2%	3.9%	3.3%	-0.6pt	△ 15.4%
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	15,707	15,845	16,431	16,429	1,059	1,072	12	1.2%
（売上高販促費率）	(Ratio to Net sales)	21.8%	21.6%	21.9%	22.2%	1.8%	1.7%	-0.1pt	△ 5.7%
設備投資額（有形・無形）	Capital expenditures	1,002	799	4,004	477	500	638	138	27.7%
減価償却費（有形・無形）	Depreciation and Amortization	1,059	1,080	1,165	1,397	1,257	1,190	△ 66	△ 5.3%

宝酒造インターナショナルグループ :Takara Shuzo International Group

（百万円 :Millions of Yen）

		2018年3月期 第2四半期 FY2018 (1Q-2Q)	2019年3月期 第2四半期 FY2019 (1Q-2Q)	2020年3月期 第2四半期 FY2020 (1Q-2Q)	2021年3月期 第2四半期 FY2021 (1Q-2Q)	2022年3月期 第2四半期 FY2022 (1Q-2Q)	2023年3月期 第2四半期 FY2023 (1Q-2Q)	前期対比 Change from FY2022(1Q-2Q) 増減 Change	前期対比 Change from FY2022(1Q-2Q) 率 YOY%
売上高	Net sales	33,822	37,527	40,477	31,286	46,734	63,730	16,995	36.4%
売上原価	Cost of sales	23,845	26,329	28,994	22,140	31,747	43,748	12,000	37.8%
（売上高原価率）	(Ratio to Net sales)	70.5%	70.2%	71.6%	70.8%	67.9%	68.6%	+0.7pt	1.1%
売上総利益	Gross profit	9,976	11,197	11,483	9,145	14,987	19,981	4,994	33.3%
販売費及び一般管理費	SG&A expenses	7,753	8,762	9,918	9,541	10,682	14,322	3,640	34.1%
（売上高販管費率）	(Ratio to Net sales)	22.9%	23.3%	24.5%	30.5%	22.9%	22.5%	-0.4pt	△ 1.7%
営業利益（△：損失）	Operating income(Δ:loss)	2,223	2,434	1,565	△ 396	4,304	5,658	1,354	31.5%
（売上高営業利益率）	(Ratio to Net sales)	6.6%	6.5%	3.9%	–	9.2%	8.9%	-0.3pt	△ 3.6%
設備投資額（有形・無形）	Capital expenditures	774	614	908	1,631	462	750	288	62.6%
減価償却費（有形・無形）	Depreciation and Amortization	455	496	585	696	837	904	67	8.0%
のれん償却額	Amortization of goodwill	170	182	173	186	187	192	5	2.8%

タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

		2018年3月期 第2四半期 FY2018 (1Q-2Q)	2019年3月期 第2四半期 FY2019 (1Q-2Q)	2020年3月期 第2四半期 FY2020 (1Q-2Q)	2021年3月期 第2四半期 FY2021 (1Q-2Q)	2022年3月期 第2四半期 FY2022 (1Q-2Q)	2023年3月期 第2四半期 FY2023 (1Q-2Q)	前期対比 Change from FY2022(1Q-2Q) 増減 Change	前期対比 Change from FY2022(1Q-2Q) 率 YOY%
売上高	Net sales	14,126	17,370	16,450	17,393	31,551	32,587	1,035	3.3%
売上原価	Cost of sales	5,965	7,049	6,121	5,565	8,056	10,562	2,505	31.1%
（売上高原価率）	(Ratio to Net sales)	42.2%	40.6%	37.2%	32.0%	25.5%	32.4%	+6.9pt	26.9%
売上総利益	Gross profit	8,160	10,321	10,329	11,827	23,495	22,025	△ 1,470	△ 6.3%
販売費及び一般管理費	SG&A expenses	7,471	7,697	7,293	8,090	9,389	11,154	1,764	18.8%
（売上高販管費率）	(Ratio to Net sales)	52.9%	44.3%	44.3%	46.5%	29.8%	34.2%	+4.5pt	15.0%
営業利益（△：損失）	Operating income(Δ:loss)	688	2,623	3,035	3,736	14,105	10,870	△ 3,234	△ 22.9%
（売上高営業利益率）	(Ratio to Net sales)	4.9%	15.1%	18.5%	21.5%	44.7%	33.4%	-11.3pt	△ 25.4%
研究開発費	R&D expenses	2,297	2,104	1,858	2,403	2,659	3,853	1,193	44.9%
（売上高研究開発費率）	(Ratio to Net sales)	16.3%	12.1%	11.3%	13.8%	8.4%	11.8%	+3.4pt	40.3%
設備投資額（有形・無形）	Capital expenditures	439	1,068	3,190	6,087	7,676	2,056	△ 5,619	△ 73.2%
減価償却費（有形・無形）	Depreciation and Amortization	1,247	1,336	1,352	1,631	1,670	1,962	291	17.4%
のれん償却額	Amortization of goodwill	236	247	250	246	245	280	34	14.2%

6. 2023年3月期第2四半期 参考資料 :Reference Data for the Second Quarter Ended September 30, 2022

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	2022年3月期 第2四半期累計	2023年3月期 第2四半期累計 Apr. 1, 2022 - Sep. 30, 2022	
	実績(a) FY2022(1Q-2Q) Actual (a)	実績(c) FY2023(1Q-2Q) Actual (c)	前期差 Change(c-a)
米ドル : US dollar	107.82	123.15	15.33
ポンド: Pound	149.78	159.58	9.80
ユーロ: Euro	129.88	134.39	4.51
人民元: Yuan	16.67	18.97	2.30
100ウォン: 100 Won	9.64	9.97	0.33
インドルピー: Rupee	1.47	1.62	0.15
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	12.82	12.82	0.00
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	80.90	90.17	9.27
ｵｰｽﾄﾗﾘｱﾄﾞﾙ :Australian dollar	83.13	88.52	5.39

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2022(1Q-2Q)
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	7,234
宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ計 Net sales of Takara Shuzo International Group	5,525
海外酒類事業 Overseas Alcoholic beverages business	856
海外日本食材卸事業 Japanese food wholesale business in overseas markets	4,811
その他および調整額 Other / Adjustment	△ 141
タカラバイオグループ 計 Net sales of Takara Bio Group	1,708
試薬 Reagents	1,541
機器 Instruments	16
受託 CDMO	36
遺伝子医療 Gene Therapy	114

② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

	2022年3月期第2四半期 実績 FY2022(1Q-2Q) Actual			2023年3月期第2四半期 実績 FY2023(1Q-2Q) Actual		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo	57,633	—	—	61,820	—	—
宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Takara Shuzo International Group	46,734	46,504	99.5%	63,730	63,455	99.5%
タカラバイオグループ Takara Bio Group	31,551	16,111	51.1%	32,587	16,288	49.9%
その他および調整額 Other / Adjustment	5,293	—	—	6,141	—	—
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	141,213	62,615	44.3%	164,279	79,744	48.5%

③ 宝酒造インターナショナルグループおよびタカラバイオグループの主要子会社の業績 :Financial Forecast of major subsidiaries

		2022年3月期第2四半期 実績 FY2022(1Q-2Q) Actual		2023年3月期第2四半期 実績 FY2023(1Q-2Q) Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	19,697	3,733	23,744	3,133
Takara Sake USA Inc.	百 万 円 :Millions of Yen	2,123	402	2,924	385
宝酒造食品	千 元 :Thousands of Yuan	28,240	1,933	17,653	△ 1,359
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	470	32	334	△ 25
トマーチン	千 ポ ン ド :Thousands of Pound	13,889	5,629	14,130	4,865
The Tomatin Distillery Co.,Ltd	百 万 円 :Millions of Yen	2,080	843	2,254	776
ｴｲｼﾞ・ｲﾝﾀｰﾅｼｮﾅﾙ	千 US ドル :Thousands of US dollar	18,652	8,611	20,034	9,129
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	2,011	928	2,467	1,124
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	104,468	12,256	128,891	12,549
FOODEX Group	百 万 円 :Millions of Yen	13,568	1,591	17,321	1,686
タザキフーズ	千 ポ ン ド :Thousands of Pound	23,083	1,451	33,353	777
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	3,457	217	5,322	124
ミューチャルトレーディング	千 US ドル :Thousands of US dollar	189,089	5,914	244,174	14,151
Mutual Trading Co., Inc.	百 万 円 :Millions of Yen	20,387	637	30,070	1,742
ニッポンフード	千 AUS ドル :Thousands of Australian dollar	26,577	1,950	29,689	2,151
Nippon Food Supplies Company Pty Ltd	百 万 円 :Millions of Yen	2,209	162	2,628	190
東京共同貿易 Tokyo Mutual Trading Co., Ltd.	百 万 円 :Millions of Yen	5,004	255	7,522	445
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S. (連結)	千 ユ ー ロ :Thousands of Euro	32,364	6,352	18,165	1,896
Takara Bio Europe S.A.S. Consolidated	百 万 円 :Millions of Yen	4,203	825	2,441	254
宝生物工程(大連)	千 元 :Thousands of Yuan	152,249	47,128	149,280	47,310
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	2,537	785	2,831	897
宝日医生物技術(北京)	千 元 :Thousands of Yuan	322,063	58,786	283,742	45,843
Takara Biomedical Technology(Beijing) Co., Ltd.	百 万 円 :Millions of Yen	5,368	979	5,382	869
ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ	百 万 ウ ォ ン :Millions of Won	6,273	1,041	7,327	1,128
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	604	100	730	112
タカラバイオDSSインド	千 ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee	470,318	83,145	451,130	50,563
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	691	122	730	81
タカラバイオUSA	千 US ドル :Thousands of US dollar	59,052	7,102	69,965	15,137
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	6,367	765	8,616	1,864

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo

(百万円 :Millions of Yen)

	対前期増減 Change from FY2022(1Q-2Q)		
	増減計 Total Change	売上差 Change in quantities	構成差 Change in sales composition
売上総利益 計 Gross profit	△ 235	+1,038	△ 1,274
(参考)原価コストダウン Reference :Cost reduction	△ 2,463	※上記構成差に含む *Included in change in sales composition	

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「△」, respectively

⑤ 宝ホールディングス(連結)要約損益計算書(p.1)における「その他」の内訳

Breakdown of "Other" segment in the Consolidated Statements of Income of Takara Holdings Inc. (Summary) (p.1)

(百万円 :Millions of Yen)

	2022年3月期第2四半期 実績 FY2022(1Q-2Q) Actual		2023年3月期第2四半期 実績 FY2023(1Q-2Q) Actual	
	売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
物流事業 Transportation	6,854	297	6,897	314
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	251	209	249	206
その他 Other	7,518	522	8,430	721
「その他」計 Total "Other"	14,624	1,029	15,577	1,243

7. 2023年3月期 業績予想 :Financial forecast for the year ending March 31, 2023

① 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	2022年3月期 FY2022 実績(a) Actual (a)	2023年3月期 FY2023_Apr. 1, 2022 - Mar. 31, 2023 8/4予想(b) Forecast announced Aug. 2022 (b)	2023年3月期 FY2023_Apr. 1, 2022 - Mar. 31, 2023 11/10予想(c) Forecast announced Nov. 2022 (c)	対前期 Change from FY2022 増減(c-a) Change (c-a)	対前期 Change from FY2022 率(c/a-1) YOY% (c/a-1)	対8/4予想 Change from forecast announced Aug. 2022 増減(c-b) Change (c-b)	対8/4予想 Change from forecast announced Aug. 2022 率(c/b-1) YOY% (c/b-1)
宝酒造 Takara Shuzo	119,710	119,781	120,134	423	0.4%	353	0.3%
宝酒造インターナショナルグループ Takara Shuzo International Group	102,186	135,488	136,907	34,720	34.0%	1,419	1.0%
タカラバイオ グループ Takara Bio Group	67,699	55,300	77,800	10,100	14.9%	22,500	40.7%
その他 Other	30,719	31,050	30,759	39	0.1%	△ 291	△ 0.9%
調整額 Adjustment	△ 19,396	△ 19,619	△ 18,600	796	–	1,019	–
売上高 Net sales	300,918	322,000	347,000	46,081	15.3%	25,000	7.8%
売上原価 Cost of sales	187,376	208,700	229,000	41,623	22.2%	20,300	9.7%
売上総利益 Gross profit	113,541	113,300	118,000	4,458	3.9%	4,700	4.1%
運送費、保管料 Transportation and storage	12,076	13,500	13,200	1,123	9.3%	△ 300	△ 2.2%
広告宣伝費 Advertising	2,510	2,600	2,400	△ 110	△ 4.4%	△ 200	△ 7.7%
販売促進費 Sales promotion	3,883	4,700	4,500	616	15.9%	△ 200	△ 4.3%
研究開発費 Research and development	6,484	8,300	9,100	2,615	40.3%	800	9.6%
管理費、その他 Other, net	45,232	52,500	53,400	8,167	18.1%	900	1.7%
販売費及び一般管理費 SG&A expenses	70,187	81,600	82,600	12,412	17.7%	1,000	1.2%
宝酒造 Takara Shuzo	4,135	4,236	3,800	△ 335	△ 8.1%	△ 436	△ 10.3%
宝酒造インターナショナルグループ Takara Shuzo International Group	8,472	10,800	11,000	2,527	29.8%	200	1.9%
タカラバイオ グループ Takara Bio Group	28,902	15,000	19,000	△ 9,902	△ 34.3%	4,000	26.7%
その他 Other	2,222	2,380	2,344	121	5.5%	△ 36	△ 1.5%
調整額 Adjustment	△ 379	△ 716	△ 744	△ 364	–	△ 28	–
営業利益(△:損失) Operating income(Δ:loss)	43,354	31,700	35,400	△ 7,954	△ 18.3%	3,700	11.7%
受取利息・配当金 Interest and Dividends income	767	850	1,000	232	30.3%	150	17.6%
その他営業外収益 Other, net	725	450	500	△ 225	△ 31.1%	50	11.1%
営業外収益 Non-operating income	1,492	1,300	1,500	7	0.5%	200	15.4%
支払利息 Interest and discounts expenses	330	300	250	△ 80	△ 24.5%	△ 50	△ 16.7%
その他営業外費用 Other, net	1,284	400	650	△ 634	△ 49.4%	250	62.5%
営業外費用 Non-operating expenses	1,615	700	900	△ 715	△ 44.3%	200	28.6%
経常利益(△:損失) Ordinary income(Δ:loss)	43,230	32,300	36,000	△ 7,230	△ 16.7%	3,700	11.5%
特別利益 Extraordinary income	4,658	250	1,000	△ 3,658	△ 78.5%	750	300.0%
特別損失 Extraordinary loss	6,928	150	300	△ 6,628	△ 95.7%	150	100.0%
税金等調整前当期純利益(△:損失) Income before income taxes(Δ:loss)	40,961	32,400	36,700	△ 4,261	△ 10.4%	4,300	13.3%
法人税、住民税及び事業税 Current income taxes	11,900	9,900	11,200	△ 390	△ 3.4%	1,300	13.1%
法人税等調整額 Deferred income taxes	△ 309						
当期純利益(△:損失) Net income(Δ:loss)	29,370	22,500	25,400	△ 3,970	△ 13.5%	2,900	12.9%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	8,601	5,200	6,400	△ 2,201	△ 25.6%	1,200	23.1%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	20,769	17,300	18,900	△ 1,869	△ 9.0%	1,600	9.2%
設備投資額(有形・無形) Capital expenditures	16,213	16,395	16,395	181	1.1%	–	–
減価償却費(有形・無形) Depreciation and Amortization	8,425	9,400	9,200	774	9.2%	△ 200	△ 2.1%
のれん償却額 Amortization of goodwill	875	1,000	1,000	124	14.3%	–	–

② 宝酒造 :Takara Shuzo

（百万円 :Millions of Yen）

	2022年3月期 FY2022 実績(a) Actual (a)	2023年3月期 FY2023_Apr. 1, 2022 - Mar. 31, 2023 8/4予想(b) Forecast announced Aug. 2022 (b)	2023年3月期 FY2023_Apr. 1, 2022 - Mar. 31, 2023 11/10予想(c) Forecast announced Nov. 2022 (c)	対前期 Change from FY2022 増減(c-a) Change (c-a)	対前期 Change from FY2022 率(c/a-1) YOY% (c/a-1)	対8/4予想 Change from forecast announced Aug. 2022 増減(c-b) Change (c-b)	対8/4予想 Change from forecast announced Aug. 2022 率(c/b-1) YOY% (c/b-1)
焼酎 Shochu	37,935	35,323	35,454	△ 2,481	△ 6.5%	131	0.4%
清酒 Sake	12,803	12,699	12,245	△ 558	△ 4.4%	△ 454	△ 3.6%
ソフトアルコール飲料 Light-alcohol refreshers	37,677	40,201	39,718	2,040	5.4%	△ 483	△ 1.2%
その他酒類 Other liquors	5,467	4,739	5,246	△ 221	△ 4.0%	507	10.7%
本みりん Hon Mirin	9,097	9,039	9,103	5	0.1%	64	0.7%
その他調味料 Other seasonings	8,560	8,734	8,727	166	1.9%	△ 7	△ 0.1%
原料用アルコール等 Raw alcohol	8,168	9,046	9,641	1,472	18.0%	595	6.6%
売上高 Net sales	119,710	119,781	120,134	423	0.4%	353	0.3%
売上原価 Cost of sales	90,898	90,904	92,194	1,295	1.4%	1,290	1.4%
売上総利益 Gross profit	28,811	28,877	27,940	△ 871	△ 3.0%	△ 937	△ 3.2%
運送費、保管料 Transportation and storage	8,134	7,936	7,804	△ 330	△ 4.1%	△ 132	△ 1.7%
広告宣伝費 Advertising	2,327	2,429	2,191	△ 136	△ 5.9%	△ 238	△ 9.8%
販売促進費 Sales promotion	2,423	2,779	2,652	228	9.4%	△ 127	△ 4.6%
研究開発費 Research and development	366	357	357	△ 9	△ 2.5%	–	–
管理費、その他 Other, net	11,425	11,140	11,136	△ 289	△ 2.5%	△ 4	△ 0.0%
販売費及び一般管理費 SG&A expenses	24,676	24,641	24,140	△ 536	△ 2.2%	△ 501	△ 2.0%
営業利益（△：損失） Operating income(Δ:loss)	4,135	4,236	3,800	△ 335	△ 8.1%	△ 436	△ 10.3%
営業外収益 Non-operating income	281	404	473	191	67.8%	69	17.1%
営業外費用 Non-operating expenses	346	339	498	151	43.6%	159	46.9%
経常利益（△：損失） Ordinary income(Δ:loss)	4,070	4,301	3,775	△ 295	△ 7.3%	△ 526	△ 12.2%
特別利益 Extraordinary gain	110	–	63	△ 47	△ 43.2%	63	–
特別損失 Extraordinary loss	1,321	169	230	△ 1,091	△ 82.6%	61	36.1%
税金等調整前当期純利益（△：損失） Income before income taxes(Δ:loss)	2,859	4,132	3,608	748	26.2%	△ 524	△ 12.7%
法人税、住民税及び事業税 Current income taxes	1,007	1,419	1,240	328	36.1%	△ 179	△ 12.6%
法人税等調整額 Deferred income taxes	△ 96						
当期純利益（△：損失） Net income(Δ:loss)	1,948	2,713	2,368	419	21.5%	△ 345	△ 12.7%
設備投資額（有形・無形） Capital expenditures	1,785	4,008	4,008	2,222	124.5%	–	–
減価償却費（有形・無形） Depreciation and Amortization	2,590	2,550	2,503	△ 87	△ 3.4%	△ 47	△ 1.8%

③ 宝酒造インターナショナルグループ :Takara Shuzo International Group

（百万円 :Millions of Yen）

	2022年3月期 FY2022	2023年3月期 FY2023_Apr. 1, 2022 - Mar. 31, 2023		対前期 Change from FY2022		対8/4予想 Change from forecast announced Aug. 2022	
	実績(a) Actual (a)	8/4予想(b) Forecast announced Aug. 2022 (b)	11/10予想(c) Forecast announced Nov. 2022 (c)	増減(c−a) Change (c-a)	率(c/a−1) YOY% (c/a-1)	増減(c−b) Change (c-b)	率(c/b−1) YOY% (c/b-1)
海外酒類事業 Overseas Alcoholic beverages business	14,063	17,658	17,944	3,880	27.6%	286	1.6%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	89,728	120,018	121,025	31,296	34.9%	1,007	0.8%
その他 Other	62	2,840	2,843	2,780	4,467.4%	3	0.1%
連結消去 Elimination	△ 1,668	△ 5,028	△ 4,906	△ 3,237	―	122	―
売上高 Net sales	102,186	135,488	136,907	34,720	34.0%	1,419	1.0%
売上原価 Cost of sales	70,045	93,456	94,122	24,076	34.4%	666	0.7%
売上総利益 Gross profit	32,140	42,032	42,785	10,644	33.1%	753	1.8%
運送費、保管料 Transportation and storage	3,490	5,092	5,031	1,540	44.2%	△ 61	△ 1.2%
広告宣伝費 Advertising	112	158	160	47	42.5%	2	1.3%
販売促進費 Sales promotion	812	1,097	1,102	289	35.7%	5	0.5%
管理費、その他 Other, net	19,253	24,885	25,492	6,238	32.4%	607	2.4%
販売費及び一般管理費 SG&A expenses	23,667	31,232	31,785	8,117	34.3%	553	1.8%
海外酒類事業 Overseas Alcoholic beverages business	3,781	4,806	4,953	1,171	31.0%	147	3.1%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	6,112	7,758	7,831	1,718	28.1%	73	0.9%
その他 Other	△ 933	1,528	1,527	2,460	―	△ 1	△ 0.1%
連結消去 Elimination	△ 487	△ 3,293	△ 3,312	△ 2,824	―	△ 19	―
営業利益(△:損失) Operating income(Δ:loss)	8,472	10,800	11,000	2,527	29.8%	200	1.9%
営業外収益 Non-operating income	297	250	256	△ 41	△ 14.0%	6	2.4%
営業外費用 Non-operating expenses	309	192	141	△ 168	△ 54.4%	△ 51	△ 26.6%
経常利益(△:損失) Ordinary income(Δ:loss)	8,461	10,858	11,115	2,653	31.4%	257	2.4%
特別利益 Extraordinary gain	3	5	―	△ 3	―	△ 5	―
特別損失 Extraordinary loss	202	3	2	△ 200	△ 99.0%	△ 1	△ 33.3%
税金等調整前当期純利益(△:損失) Income before income taxes(Δ:loss)	8,261	10,860	11,113	2,851	34.5%	253	2.3%
法人税等 Current income taxes, etc.	2,159	2,962	3,085	975	46.2%	123	4.2%
法人税等調整額 Deferred income taxes	△ 49						
当期純利益(△:損失) Net income(Δ:loss)	6,151	7,898	8,028	1,876	30.5%	130	1.6%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	783	1,013	1,044	260	33.2%	31	3.1%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	5,368	6,885	6,984	1,615	30.1%	99	1.4%
設備投資額(有形・無形) Capital expenditures	844	2,111	2,111	1,266	150.1%	―	―
減価償却費(有形・無形) Depreciation and Amortization	1,675	1,900	2,005	329	19.7%	104	5.5%
のれん償却額 Amortization of goodwill	374	394	394	19	5.1%	△ 0	△ 0.2%

（注）2022年8月4日時点で公表した通期の業績予想において、
タカラバイオグループは2022年5月12日公表の予想を据え置いております。

④ タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

	2022年3月期 FY2022 実績(a) Actual (a)	2023年3月期 FY2023_Apr. 1, 2022 - Mar. 31, 2023 5/12予想(b) Forecast announced May. 2022 (b)	2023年3月期 FY2023_Apr. 1, 2022 - Mar. 31, 2023 11/10予想(c) Forecast announced Nov. 2022 (c)	対前期 Change from FY2022 増減(c−a) Change (c-a)	対前期 Change from FY2022 率(c/a−1) YOY% (c/a-1)	対5/12予想 Change from forecast announced May. 2022 増減(c−b) Change (c-b)	対5/12予想 Change from forecast announced May. 2022 率(c/b−1) YOY% (c/b-1)
試薬 Reagents	52,479	41,010	65,106	12,627	24.1%	24,095	58.8%
機器 Instruments	1,518	1,471	1,716	197	13.0%	244	16.6%
受託 CDMO	11,426	10,212	8,356	△ 3,070	△ 26.9%	△ 1,855	△ 18.2%
遺伝子医療 Gene Therapy	2,275	2,606	2,621	346	15.2%	15	0.6%
売上高 Net sales	67,699	55,300	77,800	10,100	14.9%	22,500	40.7%
売上原価 Cost of sales	18,488	17,444	34,068	15,579	84.3%	16,623	95.3%
売上総利益 Gross profit	49,211	37,855	43,731	△ 5,480	△ 11.1%	5,875	15.5%
運送費、保管料 Transportation and storage	755	748	667	△ 88	△ 11.7%	△ 81	△ 10.9%
広告宣伝費 Advertising	58	91	51	△ 7	△ 12.3%	△ 40	△ 44.1%
販売促進費 Sales promotion	683	899	729	45	6.6%	△ 170	△ 18.9%
研究開発費 Research and development	6,109	7,820	8,713	2,603	42.6%	892	11.4%
管理費、その他 Other, net	12,702	13,295	14,569	1,866	14.7%	1,273	9.6%
販売費及び一般管理費 SG&A expenses	20,309	22,855	24,731	4,421	21.8%	1,875	8.2%
営業利益（△：損失） Operating income(Δ:loss)	28,902	15,000	19,000	△ 9,902	△ 34.3%	4,000	26.7%
営業外収益 Non-operating income	357	211	244	△ 113	△ 31.8%	32	15.3%
営業外費用 Non-operating expenses	800	111	144	△ 656	△ 82.0%	32	29.0%
経常利益（△：損失） Ordinary income(Δ:loss)	28,459	15,100	19,100	△ 9,359	△ 32.9%	4,000	26.5%
特別利益 Extraordinary income	4,476	250	902	△ 3,574	△ 79.8%	651	260.8%
特別損失 Extraordinary loss	5,403	55	75	△ 5,328	△ 98.6%	19	35.1%
税金等調整前当期純利益（△：損失） Income before income taxes(Δ:loss)	27,532	15,294	19,927	△ 7,605	△ 27.6%	4,632	30.3%
法人税、住民税及び事業税 Current income taxes	7,901	4,648	6,102	△ 1,522	△ 20.0%	1,453	31.3%
法人税等調整額 Deferred income taxes	△ 277						
当期純利益（△：損失） Net income(Δ:loss)	19,908	10,645	13,825	△ 6,083	△ 30.6%	3,179	29.9%
非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	58	45	25	△ 33	△ 57.1%	△ 20	△ 45.3%
親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	19,849	10,600	13,800	△ 6,049	△ 30.5%	3,200	30.2%
設備投資額（有形・無形） Capital expenditures	13,180	10,029	10,029	△ 3,151	△ 23.9%	−	−
減価償却費（有形・無形） Depreciation and Amortization	3,554	4,282	4,207	652	18.3%	△ 75	△ 1.8%
のれん償却額 Amortization of goodwill	500	514	599	98	19.7%	84	16.4%

8. 2023年3月期 参考資料 :Reference Data for the year ending March 31, 2023

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	2022年3月期 FY2022	2023年3月期 FY2023_Apr. 1, 2022 - Mar. 31, 2023			
	実績(a) Actual (a)	8/4予想(b) Forecast announced Aug. 2022 (b)	11/10予想(c) Forecast announced Nov. 2022 (c)	前期差 Change(c-a)	予想差 Change(c-b)
米ドル : US dollar	109.90	128.10	131.80	21.90	3.70
ポンド: Pound	151.17	162.80	158.60	7.43	△ 4.20
ユーロ: Euro	129.91	138.70	137.00	7.09	△ 1.70
人民元: Yuan	17.04	18.90	19.50	2.46	0.60
100ウォン: 100 Won	9.60	10.30	10.20	0.60	△ 0.10
インドルピー: Rupee	1.49	1.70	1.70	0.21	0.00
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	12.81	13.20	13.10	0.29	△ 0.10
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	81.77	93.40	95.30	13.53	1.90
ｵｰｽﾄﾗﾘｱﾄﾞﾙ :Australian dollar	82.50	90.80	90.00	7.50	△ 0.80

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2022
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	19,921
うち宝酒造インターナショナルｸﾞﾙｰﾌﾟ Net sales of Takara Shuzo International Group	15,666
海外酒類事業 Overseas Alcoholic beverages business	2,238
海外日本食材卸事業 Japanese food wholesale business in overseas markets	13,823
その他および調整額 Other / Adjustment	△ 395
うちタカラバイオグループ Net sales of Takara Bio Group	4,254
試薬 Reagents	3,745
機器 Instruments	85
受託 CDMO	76
遺伝子医療 Gene Therapy	346

② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

	2022年3月期通期 実績 FY2022 Actual			2023年3月期通期 予想 FY2023 Forecast		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo	119,710	—	—	120,134	—	—
宝酒造インターナショナルｸﾞﾙｰﾌﾟ Takara Shuzo International Group	102,186	101,767	99.6%	136,907	136,512	99.7%
タカラバイオグループ Takara Bio Group	67,699	33,623	49.7%	77,800	32,684	42.0%
その他および調整額 Other / Adjustment	11,322	—	—	12,159	—	—
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	300,918	135,390	45.0%	347,000	169,196	48.7%

③ 宝酒造インターナショナルグループおよびタカラバイオグループの主要子会社の業績 :Financial Forecast of major subsidiaries

		2022年3月期通期 実績 FY2022 Actual		2023年3月期通期 予想 FY2023 Forecast	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	40,704	5,887	45,471	5,117
Takara Sake USA Inc.	百 万 円 :Millions of Yen	4,473	647	5,993	674
宝酒造食品	千 元 :Thousands of Yuan	62,563	4,407	46,011	△ 2,184
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	1,066	75	897	△ 42
トマーチン	千 ポ ン ド :Thousands of Pound	25,392	9,076	33,052	12,586
The Tomatin Distillery Co.,Ltd.	百 万 円 :Millions of Yen	3,838	1,372	5,242	1,996
ｴｲｼﾞ・ｲﾝﾀｰﾅｼｮﾅﾙ	千 US ドル :Thousands of US dollar	36,953	16,934	39,578	18,016
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	4,061	1,861	5,216	2,374
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	226,841	23,558	268,267	25,681
FOODEX Group	百 万 円 :Millions of Yen	29,469	3,060	36,752	3,518
タザキフーズ	千 ポ ン ド :Thousands of Pound	53,010	2,227	69,500	2,262
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	8,013	336	11,022	358
ミューチャルトレーディング	千 US ドル :Thousands of US dollar	418,794	16,258	498,983	23,000
Mutual Trading Co., Inc.	百 万 円 :Millions of Yen	46,025	1,786	65,766	3,031
ニッポンフード	千 AUS ドル :Thousands of Australian dollar	54,177	4,040	63,614	4,900
Nippon Food Supplies Company Pty Ltd	百 万 円 :Millions of Yen	4,469	333	5,725	441
東京共同貿易 Tokyo Mutual Trading Co., Ltd.	百 万 円 :Millions of Yen	11,679	645	13,529	710
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S.(連結)	千 ユ ー ロ :Thousands of Euro	63,735	11,850	35,945	1,764
Takara Bio Europe S.A.S. Consolidated	百 万 円 :Millions of Yen	8,279	1,539	4,924	241
宝生物工程(大連)	千 元 :Thousands of Yuan	289,944	81,664	281,636	76,313
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	4,940	1,391	5,491	1,488
宝日医生物技術(北京)	千 元 :Thousands of Yuan	692,533	111,892	552,137	80,798
Takara Biomedical Technology(Beijing) Co., Ltd.	百 万 円 :Millions of Yen	11,800	1,906	10,766	1,575
ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ	百 万 ウ ォ ン :Millions of Won	12,807	2,059	14,057	2,226
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	1,229	197	1,433	227
タカラバイオDSSインド	千 ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee	676,136	99,845	616,116	28,569
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	1,007	148	1,047	48
タカラバイオUSA	千 US ドル :Thousands of US dollar	124,580	17,591	132,564	19,131
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	13,691	1,933	17,471	2,521

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo

(百万円 :Millions of Yen)

	対前期増減 Change from FY2022		
	増減計 Total Change	売上差 Change in quantities	構成差 Change in sales composition
売上総利益 計 Gross profit	△ 871	+101	△ 973
(参考)原価コストダウン Reference :Cost reduction	△ 5,376 ※上記構成差に含む *Included in change in sales composition		

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「△」, respectively

⑤ 宝ホールディングス(連結)業績予想(p.10)における「その他」の内訳

Breakdown of "Other" segment in the Consolidated Statements of Income of Takara Holdings Inc. (Summary) (p.10)

	2022年3月期通期 実績 FY2022 Actual		2023年3月期通期 予想 FY2023 Forecast	
	売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
物流事業 Transportation	13,904	613	13,371	580
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	502	416	501	414
その他 Other	16,312	1,192	16,886	1,348
「その他」計 Total "Other"	30,719	2,222	30,759	2,344